Journals / Turkish Journal of Hematology / 2021 / Cilt: 38 - Sayı: 1

Evaluation of Associated Lymphomas and Their Risk Factors in Patients with Lymphomatoid Papulosis: A Retrospective Single- Center Study from Turkey

Lenfomatoid Papülozlu Hastalarda Eşlik Eden Lenfomaların ve Risk Faktörlerinin Değerlendirilmesi: Retrospektif Tek Merkezli Bir Çalışma

Pages
49–56
Publication Date
2022-11-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Older age at the time of diagnosis of LyP is a significant risk factor for associated lymphomas.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Lymphomatoid papulosis (LyP) is an indolent skin disease with variable clinical features classified among the primary cutaneous CD30+ T-cell lymphoproliferative disorders.
📊
Key Findings & Data:Materials and Methods: The files of patients diagnosed with LyP between 1998 and 2018 in a tertiary dermatology clinic were retrospectively analyzed.
💡
Conclusion & Impact:Older age at the time of diagnosis of LyP is a significant risk factor for associated lymphomas.
🔬Design:Modeling & Simulation
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Lymphomatoid papulosis (LyP) is an indolent skin disease with variable clinical features classified among the primary cutaneous CD30+ T-cell lymphoproliferative disorders. It may show association with cutaneous and systemic lymphomas. We aimed to identify the frequency and characteristics of associated lymphomas among Turkish patients with LyP and to determine the risk factors for secondary lymphomas. Materials and Methods: The files of patients diagnosed with LyP between 1998 and 2018 in a tertiary dermatology clinic were retrospectively analyzed. Univariate and multivariate models were used to assess the possible risk factors for secondary lymphomas, such as demographic and clinical characteristics of the patients. Results: Among 61 patients (47 adults, 14 children) with LyP, a total of 22 secondary lymphomas were observed in 20 patients. Nineteen of them were adults. Mycosis fungoides (MF) was the major associated lymphoma (n=19) followed by systemic anaplastic large cell lymphoma (ALCL) (n=2) and primary cutaneous ALCL (n=1). The most common stage in patients with accompanying MF was stage IB (n=11). While 18 patients showed the classical type of MF, one patient had folliculotropic MF. When the risk factors for association between LyP and other lymphomas were evaluated, only older age was found to be a significant risk factor and existence of ulcerated lesions was found to be a negative indicator. Conclusion: LyP is not rare in the pediatric population. MF is the most common associated lymphoma in patients with LyP. Adult LyP patients are more commonly associated with secondary lymphomas than pediatric patients. Older age at the time of diagnosis of LyP is a significant risk factor for associated lymphomas.

Özet

Amaç: Lenfomatoid papüloz (LeP), primer kutanöz CD30+ T-hücreli lenfoproliferatif hastalıklar arasında sınıflandırılan, değişken klinik özellikler gösterebilen bir deri hastalığıdır. Kutanöz ve sistemik lenfomalarla birliktelik gösterebilir. Bu çalışmada LeP’li Türk hastalarda ikincil lenfomaların sıklığını, özelliklerini ve gelişimleri açısından risk faktörlerini belirlemeyi hedefledik. Gereç ve Yöntemler: Üçüncü basamak bir dermatoloji kliniğinde 1998-2018 yılları arasında LeP tanısı alan hastaların dosyaları retrospektif olarak incelendi. Hastaların demografik ve klinik özellikleri gibi ikincil lenfomalar açısından risk oluşturabilecek faktörler tek değişkenli ve çok değişkenli istatistik modeller kullanılarak araştırıldı. Bulgular: LeP’li 61 hastanın (47 yetişkin, 14 çocuk) 20’sinde toplam 22 ikincil lenfoma görüldü. Bu hastalardan 19’u yetişkindi. Mikozis fungoides (MF) en sık görülen ikincil lenfomaydı (n=19) ve onu sistemik anaplastik büyük hücreli lenfoma (ABHL) (n=2) ile primer kutanöz ABHL (n=1) takip ediyordu. Eşlik eden MF hastalarında evre en sık IB (n=11) olarak bulundu. Onsekiz hastada klasik tip MF varken, bir hastada bu kutanöz lenfomanın folikülotropik tipi gözlendi. LeP ve ikincil lenfomalar arasındaki ilişki değerlendirildiğinde, sadece “ileri yaş” anlamlı bir risk faktörü olarak bulundu. “Ülsere lezyon varlığı” ikincil bir lenfoma bulunması için negatif bir gösterge olarak değerlendirildi. Sonuç: LeP pediatrik popülasyonda nadir değildir. LeP’ye en sık eşlik eden ikincil lenfoma MF’dir. İkincil lenfomalar erişkin LeP hastalarında çocuk hastalara göre daha sık görülür. LeP tanısı sırasında yaşın büyük olması ikincil bir lenfoma için anlamlı bir risk faktörüdür.

🔖

Cite This Article

BÜYÜKBABANİ, N., BAYKAL, C., SAYAR, S. K., YAZGANOĞLU, K. D. (2022). Evaluation of Associated Lymphomas and Their Risk Factors in Patients with Lymphomatoid Papulosis: A Retrospective Single- Center Study from Turkey. Turkish Journal of Hematology, Cilt: 38 - Sayı: 1, 49–56. https://ajindex.com/articles/606566

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign--histologically malignant. Arch Dermatol 1968;97:23-30
  2. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785
  3. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-2390
  4. Sica A, Vitiello P, Sorriento A, Ronchi A, Calogero A, Sagnelli C, Troiani T, Fasano M, Dodaro CA, Franco R, Casale B, Santangelo M, Ciccozzi M, Ciardiello F, Argenziano G, Moscarella E. Lymphomatoid papulosis. Minerva Med 2020;111:166-172
  5. Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, Olsen E, Kim YH, Dummer R, Pimpinelli N, Whittaker S, Hodak E, Cerroni L, Berti E, Horwitz S, Prince HM, Guitart J, Estrach T, Sanches JA, Duvic M, Ranki A, Dreno B, Ostheeren-Michaelis S, Knobler R, Wood G, Willemze R. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011;118:4024-4035
  6. Melchers RC, Willemze R, Bekkenk MW, de Haas ERM, Horvath B, van Rossum MM, Sanders CJG, Veraart JCJM, Putter H, Jansen PM, Vermeer MH, Quint KD. Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis. J Eur Acad Dermatol Venereol 2020;34:260- 266
  7. AbuHilal M, Walsh S, Shear N. Associated hematolymphoid malignancies in patients with lymphomatoid papulosis: a Canadian retrospective study. J Cutan Med Surg 2017;21:507-512
  8. Fernández-de-Misa R, Hernández-Machín B, Servitje O, Valentí-Medina F, Maroñas-Jiménez L, Ortiz-Romero PL, Sánchez Schmidt J, Pujol RM, Gallardo F, Pau-Charles I, García Muret MP, Pérez Gala S, Román C, Cañueto J, Blanch Rius L, Izu R, Ortiz-Brugués A, Martí RM, Blanes M, Morillo M, Sánchez P, Peñate Y, Bastida J, Pérez Gil A, Lopez-Lerma I, Muniesa C, Estrach T. First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. Clin Exp Dermatol 2018;43:137-143
  9. Cordel N, Tressières B, D’Incan M,